IDWEEK 2022 Poster # 1255109



Ji Young Lee, MD¹; Eun Hwa Kim, MS²; Myeongjee Lee, PhD²; Jee Yeon Baek, MD¹; Je Hee Shin, MD¹; Sung Min Lim, MD¹; Sung Min Lim, MD¹; Sung Min Lim, MD¹; Je Hee Shin, MD¹ ¹ Department of Pediatrics, ² Biostatistics Collaboration Unit, ³ Division of Biostatistics, ⁴ Institute for Immunology and In Marine Institute for Immunology and In Marine Institute for Immunology and In Marine Institute for Immunology and Inference of Medicine, Seoul, South Korea

Background					
 Tetracyclines, despite clinical usefulness, are prohibited in use under children under 12 years in South Korea and UK, and 8 in USA due to risk of dental discoloration and enamel dysplasia (dental abnormalities). 		A 0			
✓ There is insufficient evidence to assess whether the risk of dental abnormalities is increased in children aged 8–12 years.		incidence rate .0 .0			
Objectives		.0			
✓ To assess the incidence of dental discoloration and enamel dysplasia in Korean children prescribed tetracyclines (TC).					
 To investigate whether the risk of dental abnormalities was greater in TC-exposed children compared to the general population. 					
Methods					
✓ Study design: Nationwide, population-based retrospective study					
✓ Data source: National Health Insurance Service (NHIS)					
✓ Subjects: Children aged 0–12 years with a claim for TC prescription between, who were prescribed at least		(A gr			
one day between January 2008 and December 2020 Children aged 0-12 years with tetracyclines prescription between January 2008 and December 2020 N=71,538		(B ar			
A wash-out period of 1-year, 2008, N=7,615 Children aged 0-12 years with tetracyclines prescription between January 2009 and December 2020 Excluded Diagnosis of dental appormalities		(C da			
Final ask ant					
Final cohort prescription, N=134 N=56,990 • Less than 6 months of follow-up after tetracycline prescription, N=2,708 • Death within 6 months after tetracyclines prescription, N=91					
0-7 years 8-12 years N=1,735 N=55,255 (3.0%) (97.0%)		(E e)			
0-3 years 4-7 years N=439 N=1,296 (0.8%) (2.3%)					
 Primary outcome: Incidence of dental abnormalities 6 months after TC exposure 					
 Secondary outcome: Standardized incidence rates (SIR) of dental abnormalities compared to general population 					

Dental Discoloration and Enamel dysplasia after Tetracycline Exposure in Children: A Nationwide Population-Based Study in Korea

Results

Cumulative incidence rate of dental abnormalities after TC exposure



A)Comparison of the cumulative incidence rate between the 0–7 (blue) and 8–12 years age roups (green)

B)Subgroup analysis of the cumulative incidence rate by age group: 0–3 (blue), 4–7 nd 8–12 years (green).

C) Comparison of the cumulative incidence rate according to duration of TC expose ays, blue; 8–14 days, orange; and ≥15 days, green)

)) The cumulative incidence rate in the 0–7 years age group according to the durati xposure.

E)The cumulative incidence rate in 8–12 years age group according to the duration xposure.

Trend of TC prescription in Korea

Since the implementation of Drug Utilization Review (DUR) in 2007, which m inspects the prescription of contraindicated drugs, the number of children aged with TC prescription sharply decreased from 5,215 in 2008 to 3,216 in 2020.

Among the prescribed TC, doxycycline and minocycline, were most commonly (61% and 35%, respectively)

Summary of Results Incidence rate of dental abnormalities in children ✓ The incidence rate of dental abnormalities after TC exposure was 153 per 100,000 person-years in Korean with TC exposure children aged 0–12 years during 12 year-period. ✓ The incidence of dental abnormalities in the 8–12 years age group was approximately 80% lower than that in the 0–7 years group. ✓ The 5- and 10-year cumulative incidence rates of dental abnormalities after TC exposure was 4.1% and 5.7% respectively in 0-7 years age group and 0.8% and 1.3%, 78.9) respectively in 8-12 years age group. 185.4) ✓ When the duration of TC exposure was limited to less 055.8) than 15 days, there was no significantly increased risk .55.7) compared to the general population. 66.43) • *Age at the time of dental abnormality diagnosis • # Age at the time of tetracycline prescription • N/A: not applicable Conclusion ✓ This is the largest investigation to determine the incidence of dental abnormalities in tetracycline-Ratio exposed children. \checkmark TC is especially important therapeutic option for macrolide resistant-*Mycoplasma pneumoniae* (MRMP), which is emerging in the Asia-Pacific region. 0) 3) ✓ Our findings suggest that some countries, including Korea, need to reconsider the 8–12 years age restriction for tetracyclines such as doxycycline by lowering it from 12 to 8 years. ✓ Further studies using match-controlled methods should be conducted to substantiate our finding that the potential risk of tetracyclines in children is lower than expected to remove the age restriction.

Age * (years)	0–3	4–7	8–12	13–17	18–23	Tota I	Person-years	Incidence ra Per 100,000 person-y (95% Confidence rval)
Age#								
0–7	5	24	17	N/A	N/A	46	6268.2	733.9 (537.3–9)
0–3	5	6	1	N/A	N/A	12	1768.3	678.6 (350.7–11
4–7	N/A	18	16	N/A	N/A	34	4500.0	755.6 (523.3–10
8–12	N/A	N/A	26	376	97	499	349886.8	142.6 (130.4–1
Total	5	24	43	376	97	545	356155.0	153.0 (140.44-16

Standardized	incidence	ratio	(SIR) of	dental
	abnorma	lities		

	Age at the time of	Standardized Incidence
(orange),	prescribing tetracyclines	(95% CI)
	All	
sure (0–7	0-7 years	1.08 (0.69—1.60
	8-12 years ⊢•–	0.44 (0.30-0.63
		0.57 (0.16-1.43
ion of TC	4-7 years	1 30 (0.10-1.4)
	8-12 years ⊢●⊣	0.44 (0.30-0.63
ion of TC	Tetracyclines < 15 days	
	0-7 vears	1.04 (0.65—1.57
	8-12 years ⊢●–	0.45 (0.29—0.65
nonitors and		0 60 /0 16 1 5
$d \leq 12$ years		1.00 (0.10 - 1.00 - 1.
· , · · · ·	4-7 years -1	0.45 (0.20 0.64
		0.45 (0.29-0.65
y prescribed		2.0 2.5
	0.0 0.0 1.0 1.0	2.0 2.0

